Видео ютуба по тегу Braf V600-Mutant

Phase I/II trial of CFT1946 in mutant BRAF V600 tumors
Phase I/II trial of CFT1946 in mutant BRAF V600 tumors
Mechanism of action of CFT1946, a novel BiDAC degrader, for mutant BRAF V600 tumors
Mechanism of action of CFT1946, a novel BiDAC degrader, for mutant BRAF V600 tumors
Dr. Nathan on Long-Term Outcomes With Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Dr. Nathan on Long-Term Outcomes With Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
BRAF V600–mutant metastatic melanoma,Immune adverse events as predictors of durable response to BR
BRAF V600–mutant metastatic melanoma,Immune adverse events as predictors of durable response to BR
Encorafenib in a combination regimen for BRAF melanoma
Encorafenib in a combination regimen for BRAF melanoma
Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600–Mutant Disease
Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600–Mutant Disease
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD
Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD